US-Based Data Show AstraZeneca’s COVID-19 Vaccine Is Effective

Results recently culled from a large clinical trial conducted in the United States show that the COVID-19 vaccine created in partnership by AstraZeneca and the University of Oxford is 79% effective at preventing COVID-19 illness, and no  significant side effects were found among trial participants. AstraZeneca is expected to request Emergency Use Authorization from the US Food and Drug Administration shortly. Public health officials hope these results—which are based on a trial with more than 32,000 subjects—will boost confidence in the vaccine across the world. Some countries have stopped using the AstraZeneca immunization due to concerns about the incidence of blood clots. The AstraZeneca vaccine offers significant benefits including low cost and basic storage requirements. Click here to read more.